Latest
AFPI Responds to Critics as Food Companies Commit to Removing Synthetic Dyes
Washington, D.C.—Today, the America First Policy Institute (AFPI) issued the following statement from Stacey Schieffelin, Chair of America First Women's Initiative:
TrumpRx Saves American Patients Money on Prescription Drugs
American patients are tired of both their high health costs and the middlemen preventing from getting what they need. They complain that their health benefits are not covering medicines and treatment when they need it, or having to pay extraordinary out-of-pocket costs before their health insurance benefits kick in.
Analysis of Title VII: Lowering Prescription Drug Costs & Other Related Provisions
The Great Health Care Plan, introduced by the Trump Administration, fundamentally supports 1) giving Americans their health dollars, 2) giving Americans transparency into costs, and 3) giving Americans more options for how to pay for their healthcare. Title VII in H.R. 7148 and other related healthcare provisions in this bill that passed the House on January 22, 2026, achieve many of the goals outlined in President Trump’s plan.
Promises Kept: Protecting American Children from Chemical and Surgical
The Trump Administration has set out to purge gender ideology from the federal government and dismantle the social institutions that indoctrinate children as well as to ban the practice of child chemical and surgical mutilation and impose sufficient pressure on the medical community to abandon it as a discipline. Given the irreversible consequences of these procedures, it’s not surprising that President Trump’s policies command robust support—polls show that 56% of Americans favor banning interventions like puberty blockers, hormone therapies and surgeries on children.[1]
AFPI Celebrates the End of Human Fetal Tissue in Taxpayer-Funded Research
AFPI applauds the NIH for ending the use of human fetal tissue in taxpayer funded, NIH supported research. Instead, the Trump Administration is advancing innovative technologies to conduct more effective bio medical testing without the cost to unborn life. This decision marks a turning point for gold-standard science in the United States.